Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 6/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15078760 | 0.87 | TLR4 (0.48) | TLR4TLR2LTB4R | |
| SCHEMBL16451222 | 0.86 | TLR4 (0.47) | TLR4TLR2LTB4R | |
| SCHEMBL16451112 | 0.86 | TLR4 (0.47) | TLR4TLR2LTB4R | |
| SCHEMBL15078749 | 0.86 | PLA2G2A (0.42) | LTB4RPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL15078745 | 0.84 | PLA2G2A (0.43) | LTB4RPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL17805528 | 0.83 | LTB4R (0.39) | TLR4TLR2LTB4R | |
| SCHEMBL17831481 | 0.83 | LTB4R (0.39) | TLR4TLR2LTB4R | |
| SCHEMBL17805702 | 0.83 | LTB4R (0.39) | TLR4TLR2LTB4R | |
| SCHEMBL18053751 | 0.81 | KMT2A (0.47) | TLR4TLR2LTB4R | |
| SCHEMBL18053735 | 0.81 | KMT2A (0.47) | TLR4TLR2LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | TBCA, TBCB, BTD | TLR4 201/4885TLR2 720/4885LTB4R 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.